Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 QT/QTc Study in CRPC
NCT05607693Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezvilutamide in castration-resistant prostate cancer (CRPC), sponsored by Hengrui. Primary endpoints: Delta QTc Fridericia (QTcF) at Day 17 and Concentration-delta QTcF relationship at Day 17. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05607693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607693.